ASH 2023 | Investigating the economic burden associated with treating older patients with newly diagnosed AML
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, comments on the magnitude of the economic burden associated with treating acute myeloid leukemia (AML) in elderly patients. Although the costs of treatment and healthcare resource utilization (HRU) are substantial during all treatment phases, the greatest financial and resource burdens after initial treatment occur following disease relapse. Dr Brunner briefly discusses how the economic burden and HRU associated with the treatment of these patients could be reduced. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Acceleron, Agios, Celgene/BMS, Keros Therapeutics, Novartis, Taiho, Takeda, Gilead
Research Funding: Agios, AstraZeneca, Celgene/BMS, GSK, Janssen, Novartis
